Novartis Reports Two Child Tumour Cases Linked to Zolgensma
Novartis said it received nine tumour reports overall and that two cases in children showed evidence of a link to its gene therapy for spinal muscular atrophy.
Swiss drugmaker Novartis BX:NOT said on Friday that two cases of tumours in children showed evidence of being linked to its gene therapy drug Zolgensma, which is used to treat patients less than 2 years old with spinal muscular atrophy.The company said it had received nine reports overall of tumour…